SCHEMBL6791153

SCHEMBL6791153

CC1(C(O)c2ccc(-c3ccccc3)cc2)NC(=O)NC1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 4/20 0.41
MMP9 P14780 4/20 0.41
MMP8 P22894 1/20 0.41
MMP3 P08254 1/20 0.41
PTGS2 P35354 1/20 0.40
ALDH1A1 P00352 2/20 0.38
CACNA1F O60840 1/20 0.38
MAPT P10636 1/20 0.38
CYP2C9 P11712 1/20 0.38
HTR2A P28223 1/20 0.38
HRH1 P35367 1/20 0.38
SCN1A P35498 1/20 0.38
SCN4A P35499 1/20 0.38
BLM P54132 1/20 0.38
PMP22 Q01453 1/20 0.38
CACNA1D Q01668 1/20 0.38
KCNH2 Q12809 1/20 0.38
CACNA1S Q13698 1/20 0.38
CACNA1C Q13936 1/20 0.38
SCN5A Q14524 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6789361 1.00 MMP2 (0.41) MMP2MMP9MMP8MMP3PTGS2
SCHEMBL6791227 1.00 MMP2 (0.41) MMP2MMP9MMP8MMP3PTGS2
SCHEMBL6793526 0.87 CA12 (0.40) MMP2MMP9MMP8
SCHEMBL6790620 0.87 MMP2 (0.43) MMP2MMP9MMP8MMP3AKR1B1
SCHEMBL6795148 0.87 AKR1B1 (0.35) ALDH1A1AKR1B1
SCHEMBL8339982 0.86 PGR (0.41) MMP2MMP9MMP8MMP3MAPT
SCHEMBL6792396 0.86 PTGER3 (0.46)
SCHEMBL6798425 0.85 CYP17A1 (0.37) ALDH1A1MAPTCYP3A4
SCHEMBL6791854 0.85 MKNK1 (0.40) MMP2MMP9MMP8MMP3ALDH1A1
SCHEMBL6835790 0.85 FFAR1 (0.41) MMP2MMP9MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147573-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-29 US disclosed
US-20040110809-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-06-10 US disclosed
EP-1370536-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
EP-1370538-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
WO-2002074752-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed
WO-2002074750-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110809-A1 Metalloproteinase inhibitors MMP9, MMP2, MMP3 MMP2 2/4885MMP9 1/4885MMP8 19/4885
US-20040147573-A1 Metalloproteinase inhibitors MMP12, MMP7, MMP10 MMP2 11/4885MMP9 8/4885MMP8 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.